Understand the source comparison
Clinical Trial Data: Mazdutide vs Semaglutide, Liraglutide, and Retatrutide
Direct head-to-head trials between mazdutide and other peptides are limited, but cross-trial comparison using equivalent BMI populations provides actionable insight. The table below compares mean weight reduction, trial duration, hepatic fat reduction, and adv
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Direct head-to-head trials between mazdutide and other peptides are limited, but cross-trial comparison using equivalent BMI populations provides actionable insight. The table below compares mean weight reduction, trial duration, hepatic fat reduction, and adverse event profiles across five peptides at their highest tested doses.
- Mazdutide 6mg
- GLP-1/Glucagon dual agonist
- 20.2%
- 48 weeks
- 58%
- 38%
- Fastest hepatic fat clearance; strong thermogenic effect; moderate nausea during titration
- Tirzepatide 15mg
- GIP/GLP-1 dual agonist
- 20.9%
- 72 weeks
- 42%
- 25–50%
- Highest total weight loss; superior glycemic control; slower hepatic effect
- Semaglutide 2.4mg
- GLP-1 single agonist
- 14.9%
- 68 weeks
- 35%
- 30–45%
- Gold standard for appetite suppression; proven cardiovascular benefit; limited thermogenesis
- Liraglutide 3.0mg
- 8.0%
- 56 weeks
- Not measured
- 40%
- Older generation; less effective than newer peptides; high injection frequency (daily)
- Retatrutide 12mg
- GLP-1/GIP/Glucagon triple agonist
- 24.2%
- 62%
- 45–55%
- Highest weight loss magnitude; highest adverse event rate; investigational only
- Retatrutide deserves specific mention. It's a triple agonist (GLP-1, GIP, glucagon) that combines mazdutide's glucagon pathway with tirzepatide's GIP mechanism. Phase 2 data showed 24.2% mean weight reduction at 48 weeks, the highest recorded in any obesity trial to date. The trade-off: adverse event rates approaching 55%, including persistent nausea and elevated heart rate from sustained glucagon-driven thermogenesis. Retatrutide is investigational and not available through compounding pharmacies. Mazdutide offers similar glucagon-driven effects with a more tolerable side effect profile.
- Semaglutide remains the most extensively studied GLP-1 peptide, with cardiovascular outcome trials (SELECT) demonstrating 20% reduction in major adverse cardiac events in obese adults. Mazdutide and tirzepatide lack equivalent long-term safety data. They're effective for weight and metabolic outcomes but haven't been studied across five-year timeframes. For research applications prioritizing short-term metabolic endpoints, mazdutide's dual mechanism offers advantages. For long-term clinical use, semaglutide's safety profile is unmatched.